Serum levels of soluble surface markers AXL and C-MET, described for cancer stem cells in rectal cancer, possibly can correlate with clinicopathological characteristics and patient outcome data with respect to neoadjuvant chemoradiotherapy. This evidence concerns the gene AXL and rectal cancer.